GGrantIndex
← Leaderboards

Francisco Robert

University Of Alabama At Birmingham

$1,276,857
Attributed
$1,276,857
Total exposure
9
Grants
1
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $16.7K · FY200506
$20K$15K$10K$5K$0
'05
'06

Funding mix

By agency

NIH$1,276,857 · 9

By mechanism

M01$1,276,857 · 9

Top collaborators

No co-investigators on record.

Most similar at University Of Alabama At Birmingham

Same institution · by research overlap

Others in their field

Top investigators on “Neoplasm /Cancer Chemotherapy

Research focus

Neoplasm /Cancer ChemotherapyHuman Therapy EvaluationHuman SubjectClinical ResearchNonsmall Cell Lung CancerClinical TrialsAntineoplasticsDosageDrug Screening /EvaluationDrug Adverse EffectClinical Trial Phase IPharmacokineticsCombination ChemotherapyHead /Neck NeoplasmRenal Cell CarcinomaIntravenous AdministrationKidney NeoplasmsMesotheliomaMetastasisMonoclonal AntibodyCamptothecinNeoplastic GrowthNeoplastic ProcessBladder Neoplasm

Grant awards (20)

PHASE I DEXAMETHASONE/CARBOPLATIN/GEMCITABINE UNTREATED IIIB/IV NSCLC$1,880
M01 · FY2006 · RR · contact PI
PHASE I DEXAMETHASONE/CARBOPLATIN/GEMCITABINE UNTREATED IIIB/IV NSCLC$16,738
M01 · FY2005 · RR
ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA$175,256
M01 · FY2002 · RR
PNU 214936 IN ADVANCED NON SMALL CELL LUNG CANCER$175,256
M01 · FY2002 · RR
EGFR ANTIBODY 225 IN METASTATIC RENAL CELL CARCINOMA$175,256
M01 · FY2002 · RR
90YCC49 MONOCLONAL ANTIBODY IN ADVANCED NONSMALL CELL LUNG CANCER$0
M01 · FY2002 · RR
9 AMINOCAMPTOTHECIN IN SOLID TUMORS$0
M01 · FY2002 · RR
EGFR ANTIBODY 225 IN METASTATIC RENAL CELL CARCINOMA$175,256
M01 · FY2001 · RR
PNU 214936 IN ADVANCED NON SMALL CELL LUNG CANCER$175,256
M01 · FY2001 · RR
ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA$175,256
M01 · FY2001 · RR
9 AMINOCAMPTOTHECIN IN SOLID TUMORS$0
M01 · FY2001 · RR
90YCC49 MONOCLONAL ANTIBODY IN ADVANCED NONSMALL CELL LUNG CANCER$0
M01 · FY2001 · RR
EGFR ANTIBODY C225 WITH IRRADIATION IN ADVANCED HEAD &NECK SQUAMOUS CELL CANCER$29,529
M01 · FY2000 · RR
ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA$29,529
M01 · FY2000 · RR
90YCC49 MONOCLONAL ANTIBODY IN ADVANCED NONSMALL CELL LUNG CANCER$29,529
M01 · FY2000 · RR
EGFR ANTIBODY 225 IN METASTATIC RENAL CELL CARCINOMA$29,529
M01 · FY2000 · RR
CISPLATIN,DEXAMETHASONE &GEMCITABINE IN RELAPSED OR REFRACTORY NON HODGKIN'S$29,529
M01 · FY2000 · RR
PNU 214936 IN ADVANCED NON SMALL CELL LUNG CANCER$29,529
M01 · FY2000 · RR
9 AMINOCAMPTOTHECIN IN SOLID TUMORS$29,529
M01 · FY2000 · RR
TRIAL OF MMP INHIBITOR AG3340 W PACLITAXEL AND CARBOPLATIN IN NSC LUNG CANCER$0
M01 · FY2000 · RR